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Aims The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treat-
ment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative trial in heart
failure (HF) to date.
Methods
and results
We looked at five regions: North America (NA) 622 (8%), Western Europe (WE) 1680 (20%), Central/Eastern Europe/
Russia (CEER) 2762 (33%), Latin America (LA) 1413 (17%), and Asia-Pacific (AP) 1487 (18%). Notable differences
included: WE patients (mean age 68 years) and NA (65 years) were older than AP (58 years) and LA (63 years) and
had more coronary disease; NA and CEER patients had the worst signs, symptoms, and functional status. North American
patients were the most likely to have a defibrillating-device (53 vs. 2% AP) and least likely prescribed a mineralocorticoid
receptor antagonist (36 vs. 61% LA). Other evidence-based therapies were used most frequently in NA and WE. Rates of
the primary composite outcome of cardiovascular (CV) death or HF hospitalization (per 100 patient-years) varied among
regions: NA 13.5 (95% CI 11.7–15.6), WE 9.6 (8.6–10.6), CEER 12.3 (11.4–13.2), LA 11.2 (10.0–12.5), and AP 12.5
(11.3–13.8). After adjustment for prognostic variables, relative to NA, the risk of CV death was higher in LA and AP
and the risk of HF hospitalization lower in WE. The benefit of sacubitril/valsartan was consistent across regions.
Conclusion There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background
therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan.
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Introduction
The declining risk of adverse outcomes in patients with heart failure
(HF) and reduced ejection fraction (HF-REF), resulting from the cu-
mulative benefit of treatments over time, has meant that contem-
porary randomized controlled clinical trials require greater
numbers of participants and longer follow-up to accrue the number
of events needed to test the effect of new therapies.1 In order to
recruit a sufficient number of patients in a timely manner, and to im-
prove generalizability of results, these trials now include participants
from many different regions of the world.2 On the other hand, geo-
graphical differences in demographics, race, ethnicity, other patient
characteristics, aetiology of HF, co-morbidity, health care systems,
physician-practice, and especially background therapy can raise
questions about the applicability of the results of the trial in certain
regions of the world.2– 14 In particular, there has been controversy
about the effect of certain treatments in patients from the USA
compared with those from the rest of the world.3,15– 17
The prospective comparison of Angiotensin Receptor-neprilysin
inhibitor with Angiotensin-converting–enzyme inhibitor to Deter-
mine Impact on Global Mortality and morbidity in Heart Failure trial
(PARADIGM-HF) is the largest trial in patients with HF and HF-REF
to date and it is the most globally representative, with 8400 pa-
tients enrolled in 47 countries on six continents.18 Our aim was
to evaluate geographical differences in patient characteristics (age,
sex, background pharmacotherapy, and comorbidity) and event
rates. We also wanted to examine the effect of sacubitril/valsartan
(formerly known as LCZ696) according to geographical region. Our
hypothesis was that patient characteristics and outcomes would
vary by geographic region in PARADIGM-HF but that the effect of
sacubitril/valsartan, compared with enalapril, would not.
Methods
The design, baseline characteristics, and results of PARADIGM-HF have
been published.18 –20 The Ethics Committee of each of the 1043 partici-
pating institutions (in 47 countries) approved the protocol, and all
patients gave written, informed consent.
Study patients
Briefly, patients had New York Heart Association (NYHA) classes II–IV
symptoms, a left ventricular ejection fraction (LVEF) ≤40% and modestly
elevated plasma B-type natriuretic peptides. Patients were required to be
taking an angiotensin converting enzyme inhibitor or angiotensin receptor
blocker in a dose equivalent to enalapril 10 mg daily for at least 4 weeks
before screening, along with a stable dose of a b-blocker (unless contra-
indicated or not tolerated) and a mineralocorticoid antagonist (MRA), if
indicated. Key exclusion criteria included a systolic blood pressure (SBP)
,95 mmHg, a serum potassium .5.4 mmol/L, or an estimated glomeru-
lar filtration rate (eGFR) ,30 mL/min/1.73 m2 at randomization.
Trial outcomes
The primary outcome was a composite of death from CV causes or a
first hospitalization for HF. The secondary outcomes included death
from any cause and change from baseline to 8 months in the Kansas
City Cardiomyopathy Questionnaire clinical summary score
(KCCQ-CSS). In the present study, we examined the primary compos-
ite outcome and its components, as well as all-cause death. We further
determined the proportion of patients experiencing a five or greater
points reduction in their KCCQ-CSS as this is considered to be a clin-
ically important deterioration in health-related quality of life (HRQL).21
Safety outcomes included hypotension, elevation of serum creatinine,
hyperkalaemia, cough, and angioedema, as previously reported.18 We
also reported total number of adverse, and serious adverse events
according to geographic region. Furthermore, we assessed length of
stay for all-cause hospitalizations during the study, and total days alive
and out of hospital in the first year (Figure 1).
Geographic regions
The following geographic regions were examined: North America (NA),
Western Europe (WE), Central/Eastern Europe/Russia (CEER), Latin
America (LA), and the Asia-Pacific (AP) region. The countries in each
of these regions are listed in Appendix.
Statistical analysis
Data are reported as mean+ SD or median and interquartile ranges
and as frequencies and percentages for categorical variables. Student’s
t-tests were used to compare baseline variables between regions.
Cox proportional hazard models were used to estimate hazard ratios
(HRs) with 95% confidence intervals (CIs) for the time-to-event end-
points, and logistic regression analysis for the binomial endpoint of
≥5 point decline in KCCQ-CSS at 8 months follow-up. In analyses of
treatment effect, the primary variable of interest was the interaction
P-value for randomized treatment × geographic region. For analyses
comparing risk according to region, we did unadjusted analyses and ana-
lyses including multivariable adjustment for treatment effect and other
variables known to be predictors of risk in patients with HF-REF (see
Supplementary material online, List). A two-tailed P-value of ,0.05
was considered significant. Statistical analyses were performed using
STATA, College Station, Texas, version 14.0.
Results
Of 8399 patients in PARADIGM-HF, 622 (7%) were randomized in
NA, 1680 (20%) in WE, 2762 (33%) in CEER, 1413 (17%) in LA, and
1487 (18%) in the AP region.
Baseline characteristics
The majority of characteristics differed across regions (Table 1 and
see Supplementary material online, Tables A and B).
Age, sex, and race/ethnicity
Patients in WE, who were the most elderly (with a mean age 68.3
years), were an average of 10.5 years older than those enrolled in
AP. The proportion of women was highest in LA (27%) and lowest
in NA (17%). The proportion of patients who were black was
highest in NA (19%).
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Social habits
The proportion of current smokers was highest in NA (17%) and
lowest in LA (10%). Daily alcohol consumption (≥1 unit) was high-
est in WE (24%) and ≤10% in all other regions.
Heart failure status
The proportion of patients with mild vs. more severe symptoms also
varied by region; whereas ,15% of patients in most regions had
moderate-to-severe symptoms, 20% of patients enrolled in NA
were in NYHA class III/IV and this proportion was highest (44%) in
CEER. The mean KCCQ-CSS (scales 0–100, with 0 equating to worst
HRQL) was lowest (worst) in CEER (68) and NA (72), compared with
the other regions; the mean KCCQ-CSS was highest in AP (79). The
SD around the mean KCCQ-CSS varied also among regions and this
was not explained only by the number of patients in each region.
Patients from CEER were most likely to report dyspnoea and fa-
tigue and have signs of congestion. However, mean LVEF (32%) was
highest in this region. NT-proBNP concentration was lower in pa-
tients from CEER, compared with most other regions, although
the differences between regions were modest. The proportion of
patients with a history of HF hospitalization varied substantially by
region, being highest in CEER (71%) and lowest in LA (54%).
Anthropometric and physiological measures
Body mass index varied by region, being highest in NA (31 Kg/m2)
and lowest in AP (24 kg/m2) (Table 1). Heart rate in patients without
atrial fibrillation (AF) was lowest in NA (70 b.p.m.) and WE
(68 b.p.m.) and highest in AP (75 b.p.m.), consistent with the geo-
graphical variation in b-blocker use but inversely related to digoxin
use (see below). Baseline SBP was highest in CEER (mean
126 mmHg) compared with 117 mmHg in AP and 118 mmHg in
NA and LA, consistent with geographical variation in hypertension
history (see below).
Coronary heart disease
An ischaemic aetiology was most common in CEER (70%) and NA
(62%) and least common in LA (43%). Consistent with this, history
of myocardial infarction was most frequent in CEER (50%) and
NA (54%) and least frequent in LA (32%) and AP (34%). The pro-
portions of patients with any manifestation of coronary disease
and prior coronary revascularization varied in a similar way
(Table 1).
Other co-morbidity
Co-morbidity was generally most common in NA (except a history
of hypertension and AF which was highest in CEER). Co-morbidity
was less common in LA and AP. The proportion of patients with
chronic kidney disease (CKD) was lowest in AP (27%) and mean
eGFR highest in that region (71 mL/min/1.73 m2); mean eGFR was
lowest in NA (61 mL/min/1.73 m2), where there was also the
greatest proportion with CKD (51%).
Figure 1 Kaplan–Meier plots of endpoints according to region.
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Drug, device, and other treatments
Although b-blocker use was mandated by protocol (unless contra-
indicated/not tolerated), there was still variability with the highest
rate in NA (97%) and lowest in AP (89%) (Table 2). There was
more striking variation in the use of mineralocorticoid receptor an-
tagonists—prescribed least commonly in NA (36%) and most fre-
quently in LA (65%). Digoxin use also varied greatly in patients
with no history of AF—from 6% in WE to 42% in AP. There was
less variation in digoxin use among patients with a history of AF
(range 33% WE to 55% AP).
The use of non-HF medications also varied geographically. The
highest rates of prescription of oral anticoagulants in patients with
an AF history were in Europe (WE 82%, CEER 68%) and NA
(63%) and lowest in AP (35%).
Device therapy varied substantially by region, being highest in NA
and lowest in CEER, LA, and AP. For example, a defibrillating-device
(ICD or CRT-D) had been implanted in 53% in NA but in only 7, 4,
and 2% of patients in CEER, LA, and AP, respectively. Similarly, other
guideline-recommended interventions varied by region. Influenza
vaccination in the past year was most frequently reported in NA
(51%) and WE (53%) but much less commonly elsewhere. A quarter
to a third of patients in NA and WE were enrolled in a structured
disease management programme but few patients were enrolled
elsewhere. Prescription of an exercise regimen was provided in
between a fifth and a quarter of patients in NA, WE, and CEER
but was uncommon elsewhere. These non-drug/device interven-
tions were rarely used in AP.
Heart failure outcomes
Cardiovascular death or heart failure hospitalization
The unadjusted rate of the primary endpoint varied less between re-
gions than the rate of HF hospitalization, with the following ranking
from lowest to highest: WE (9.6 per 100 patient-years), LA, CEER,
AP, and NA (13.5 per 100 patient-years). Using NA as the reference
region, and after adjustment, WE exhibited a lower risk (adjusted
HR 0.84, 95% CI 0.70, 1.01) but AP a higher risk (adjusted HR
1.36, 95% CI 1.05, 1.76). A supplementary analysis including South
Africa, Israel, and Turkey in alternative geographical regions gave
similar results (see Supplementary material online, Table D). We
also compared Eastern/Central Europe and Russia (see Supplemen-
tary material online, Table E); the crude rates of the primary end-
point were similar but mortality rates were slightly higher and
hospitalization rates lower, in Russia.
Mortality
The unadjusted rate of death from any cause varied modestly among
regionswith the followingranking fromlowest tohighest:WE(6.7per
100 patient-years), NA, CEER, AP, and LA (10.1 per 100 patient-years)
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Table 1 Baseline characteristics according to region
North America Western Europe Central/Eastern
Europe/Russia
Latin America Asia-Pacific P-value
Number of patients 622 (7%) 1680 (20%) 2762 (33%) 1413 (17%) 1487 (18%)
Age (years) 65.0+11.4 68.3+9.9 65.1+10.0 63.0+11.6 57.8+11.9 ,0.0001
Female sex, n (%) 108 (17%) 297 (18%) 641 (23%) 387 (27%) 292 (20%) ,0.0001
Caucasian, n (%) 466 (75%) 1645 (98%) 2712 (98%) 485 (34%) 11 (1%) ,0.0001
BMI (kg/m2) 31+7 29+5 30+5 27+5 24+4 ,0.0001
Heart rate (b.p.m.) 70+11 69+11 74+12 71+11 75+11 ,0.0001
Syst. BP (mmHg) 118+15 121+16 126+14 118+14 117+15 ,0.0001
eGFR (mL/min/1.73 m2) 59 (48, 71) 61 (50, 74) 67 (55, 80) 67 (55, 80) 72 (59, 85) ,0.0001
LVEF 0.27+0.07 0.30+0.06 0.32+0.05 0.28+0.06 0.28+0.06 ,0.0001
NYHA class, n (%) ,0.0001
I 23 (4%) 58 (4%) 33 (1%) 107 (8%) 119 (8%)
II 476 (77%) 1292 (77%) 1512 (55%) 1148 (81%) 1180 (79%)
III 117 (19%) 319 (19%) 1169 (42%) 156 (11%) 184 (13%)
IV 4 (0%) 7 (0%) 45 (2%) 0 (0%) 3 (0%)
KCCQ score 72+21 73+20 68+19 79+18 79+16 ,0.0001
NT-proBNP pg/mLa (IQR) 1580 (900, 3046) 1517 (857, 2888) 1599 (877, 3134) 1760 (917, 3645) 1714 (911, 3677) 0.0003
Medical history, n (%)
Ischaemic aetiology 387 (62%) 980 (58%) 1942 (70%) 611 (43%) 863 (58%) ,0.0001
HF hospitalization 400 (64%) 948 (56%) 1961 (71%) 767 (54%) 894 (60%) ,0.0001
Hypertension 522 (84%) 1050 (63%) 2395 (87%) 956 (68%) 719 (48%) ,0.0001
Atrial fibrillation 245 (39%) 744 (44%) 1428 (52%) 334 (24%) 249 (17%) ,0.0001
Diabetes 299 (48%) 597 (36%) 936 (34%) 385 (27%) 515 (35%) ,0.0001
CKD (eGFR, 60b) 319 (51%) 759 (45%) 950 (34%) 486 (34%) 397 (27%) ,0.0001
aNT-proBNP data are from the screening visit. Information on KCCQ score was only available for 7623 (92%) patients.
bmL/min/1.73 m2.
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(Table 3). Using NA as the reference and adjusting for differences
between regions in prognostic variables, patients in LA (adjusted
HR 1.62, 95% CI 1.24, 2.11) and AP (adjusted HR 1.35, 1.00, 1.82)
exhibited a higher risk of death. The findings for CV death were
similar.
Hospitalization
The unadjusted rate of HF hospitalization varied more among re-
gions with the following ranking from lowest to highest: LA (5.3
per 100 patient-years), AP, WE, CEER, and NA (10.5 per 100
patient-years). Using NA as the reference, all other regions showed
a significantly lower unadjusted risk of hospitalization. After adjust-
ment, this difference persisted only in WE (adjusted HR 0.79, 95%
CI 0.64, 0.98). Length of stay for hospitalization was shortest in NA
and WE and longest in CEER (see Supplementary material online,
Table F). Days alive and out of hospital in first year of study, varied
between 345 and 351 days, with highest number in NA.
Health-related quality of life
The proportion of patients exhibiting a decrease of ≥5 points in
KCCQ-CSS at 8 months was largest in NA, WE, and CEER (where
around a third of patients deteriorated) and smaller in LA (24%) and
AP (18%). The odds of deteriorating were significantly less in these
latter regions in unadjusted analyses, but not after multivariable
adjustment.
Consistency of effect of sacubitril/
valsartan on clinical outcomes by region
As shown in Table 4, the effect of sacubitril/valsartan was consistent
across regions for the primary composite endpoint, its components
and for all-cause mortality. The same was true for the effect of
sacubitril/valsartan on deterioration in KCCQ.
Study drug tolerability
Adverse events varied considerably by region (see Supplementary
material online, Table C). In the enalapril group, hypotension and re-
nal impairment were most common in NA, hyperkalaemia was most
common in CEER and cough most common in AP. The differences
between sacubitril/valsartan and enalapril (more hypotension and
less renal impairment and hyperkalaemia with the former) were
consistent across regions. Study drug discontinuation for reasons
other than death varied significantly by geographical region, from
32% in NA to 10% in AP.
Discussion
Although there are a few analyses of geographic variation among pa-
tients with acute HF, there is only one report from a trial, the As-
sessment of Treatment with Lisinopril and Survival study
(ATLAS), in ambulatory patients with chronic HF-REF, published
in 1998.3,7,8,10,11 No acute or chronic HF trial has been as globally
diverse as PARADIGM-HF which included patients from geograph-
ical areas under-represented in prior studies including LA and, espe-
cially, AP. More data were collected on baseline characteristics and
treatment in PARADIGM-HF than in prior trials, including infor-
mation on non-pharmacolgical/non-device recommendations, e.g.
enrolment in disease management programmes.
Baseline characteristics
We found some inevitable differences between regions (e.g. in race
and ethnicity), some possibly related to genetic background (e.g. low
prevalence of AF in AP22). It is harder to explain other differences.
Compared with NA and WE, where clinical trials were initially con-
ducted, the average patient age was lower (especially in AP) and the
proportion of women larger (especially in LA). Ischaemic aetiology
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Table 2 Pharmacological and device treatment
North
America
Western
Europe
Central/Eastern
Europe/Russia
Latin
America
Asia-Pacific P-value
Medication, n (%)
Loop-diuretic 503 (81%) 1362 (81%) 2292 (83%) 1101 (78%) 1091 (73%) ,0.0001
b-Blocker 603 (97%) 1570 (94%) 2612 (95%) 1305 (92%) 1320 (89%) ,0.0001
MRA 225 (36%) 742 (44%) 1695 (61%) 916 (65%) 830 (56%) ,0.0001
Digoxin
All 167 (27%) 307 (18%) 805 (29%) 495 (35%) 660 (44%) ,0.0001
History of AF 99 (40%) 248 (33%) 647 (45%) 171 (51%) 136 (55%) ,0.0001
No history of AF 68 (18%) 58 (6%) 155 (12%) 324 (30%) 523 (42%) ,0.0001
Oral anticoagulants
All 205 (33%) 792 (47%) 1181 (43%) 274 (19%) 143 (10%) ,0.0001
History of AF 154 (63%) 606 (82%) 964 (68%) 180 (54%) 87 (35%) ,0.0001
No history of AF 51 (14%) 186 (20%) 217 (16%) 94 (9%) 56 (5%) ,0.0001
Devices
Any CRT 130 (21%) 207 (12%) 113 (4%) 29 (2%) 42 (3%) ,0.0001
ICD or CRT-D 327 (53%) 559 (33%) 193 (7%) 61 (4%) 26 (2%) 0.0033
MRA, mineralocorticoid receptor antagonist; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; AF, atrial fibrillation.
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was least frequent in LA, which was also reported in two acute HF
trials, presumably reflecting different causes of HF on that continent,
including Chagas cardiomyopathy.7,8
Regarding HF status, we found that the greatest differences were
between CEER and the rest of the World. Specifically, CEER
patients had worse symptoms and more severe functional limitation
as evaluated by the investigators (NYHA class) and reported by
patients (KCCQ-CSS). Consistent with this, signs (dyspnoea,
oedema, and rales) and prior HF hospitalization were more com-
mon. However, patients from CEER had the highest average LVEF
and lowest NT-proBNP and, overall, examination of regional
patterns showed no clear relationship between objective measure-
ments of cardiac dysfunction and symptom frequency and physical
limitation.
As observed previously, the rate of prior coronary intervention
was highest in NA,7,8,11 followed closely by WE; patients in CEER
had less prior coronary intervention but the rates in this region
were still considerably higher than in LA and AP. Despite similar re-
commendations regarding ICD and CRT use in all major guidelines,
an even more extreme pattern of disparity of use was seen, with a
30-fold difference in use of a defibrillating-device between NA and
AP.7,8,11 Of all regional variation, use of procedures, devices, and
surgery showed the greatest differences, probably, in part, reflecting
economic differences.
Variation in HF medication use was less pronounced but was still
substantial, at least for MRAs. Prescription of MRAs showed exactly
the opposite pattern to use of devices i.e. was least common in NA
and WE and most frequent in the other regions with lower device
use. Patients in NA and WE had the lowest eGFR (and highest
proportion of patients with CKD) which may have led to reluctance
to prescribe, although the entry eGFR in PARADIGM-HF would
not have precluded safe use of a MRA, and other explanations
may exist.23 Among patients without a history of AF, there was
also an almost seven-fold difference in digoxin prescription, with
the highest use in AP (42%) and lowest use in WE (6%), illustrating
the dramatic decline in digitalis glycoside use in certain regions of the
world (in ATLAS 80% of sinus rhythm patients in NA and 57% in
continental Europe were treated with digoxin).3
Of non-HF drugs, the greatest variation was in use of oral antic-
oagulants which were much less frequently prescribed in AP, where
under-treatment of AF patients with these agents has been high-
lighted recently.24
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Table 3 Event rate (per 100 patient-years) and risk of study endpoints according to region (North America reference
region)
North
America
Western
Europe
Central/Eastern
Europe and Russia
Latin America Asia-Pacific
No. of patients 622 1680 2762 1413 1487
HF hospitalization or cardiovascular death 185 358 694 309 369
Event rates per 100 patient-years (95% CI) 13.5 (11.7–15.6) 9.6 (8.6–10.6) 12.3 (11.4–13.2) 11.2 (10.0–12.5) 12.5 (11.3–13.8)
Unadjusted HR 1.00 (ref.) 0.71 (0.59–0.85) 0.90 (0.76–1.06) 0.81 (0.67–0.97) 0.91 (0.76–1.08)
Adjusteda HR 1.00 (ref.) 0.84 (0.70–1.01) 1.07 (0.89–1.29) 1.16 (0.92–1.46) 1.36 (1.05–1.76)
HF hospitalization 144 244 402 146 192
Event rates per 100 patient-years (95% CI) 10.5 (8.9–12.4) 6.5 (5.7–7.4) 7.1 (6.5–7.8) 5.3 (4.5–6.2) 6.5 (5.6–7.5)
Unadjusted HR 1.00 (ref.) 0.62 (0.50–0.76) 0.66 (0.55–0.80) 0.48 (0.38–0.61) 0.60 (0.48–0.75)
Adjusteda HR 1.00 (ref.) 0.79 (0.64–0.98) 0.94 (0.75–1.17) 0.81 (0.60–1.09) 1.01 (0.72–1.40)
Cardiovascular death 90 192 419 236 252
Event rates per 100 patient-years (95% CI) 5.8 (4.7–7.2) 4.8 (4.1–5.5) 6.8 (6.2–7.5) 8.2 (7.2–9.3) 8.0 (7.1–9.1)
Unadjusted HR 1.00 (ref.) 0.91 (0.71–1.6) 1.17 (0.93–1.47) 1.41 (1.10–1.79) 1.38 (1.08–1.75)
Adjusteda HR 1.00 (ref.) 0.92 (0.71–1.19) 1.25 (0.97–1.62) 1.74 (1.29–2.36) 1.71 (1.22–2.39)
All-cause mortality (no. of events) 123 271 510 291 279
Event rates per 100 patient-years (95% CI) 8.0 (6.7–9.5) 6.7 (6.0–7.6) 8.3 (7.6–9.1) 10.1 (9.0–11.3) 8.9 (7.9–10.0)
Unadjusted HR 1.00 (ref.) 0.85 (0.69–1.05) 1.05 (0.86–1.28) 1.28 (1.04–1.59) 1.12 (0.91–1.39)
Adjusteda HR 1.00 (ref.) 0.92 (0.74–1.15) 1.11 (0.88–1.38) 1.62 (1.24–2.11) 1.35 (1.00–1.82)
Significant worsening in KCCQ clinical score
(≥5) at 8 monthsb
208 (34%) 564 (34%) 870 (32%) 338 (24%) 264 (18%)
Unadjusted OR 1.00 (ref.) 1.01 (0.83–1.22) 0.91 (0.76–1.10) 0.63 (0.51–0.77) 0.43 (0.35–0.53)
Adjusteda OR 1.00 (ref.) 1.09 (0.89–1.34) 0.97 (0.79–1.20) 0.88 (0.68–1.12) 0.98 (0.74–1.30)
Information on KCCQ score was only available for 7623 (92%) patients.
ICD, ischaemic aetiology and history of myocardial infarction, diabetes, AF, and stroke.
aModel adjusted for age, sex, treatment arm, race, HF duration, heart rate, SBP, body mass index, NYHA class, ejection fraction, KCCQ score, and glomerular filtration rate.
bScores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100 (higher scores indicating fewer symptoms).
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The use of other guideline recommendations, including influenza
vaccination, exercise prescription, and enrolment in disease man-
agement programmes, varied greatly between regions. For example,
influenza vaccination was used in around half of patients in NA and
WE but rarely outside these regions. Similar patterns were
observed for the other non-drug/non-device recommendations.
Collectively, our data show the use of guideline-recommended
therapies is highest in NA and WE, with less application in CEER
and LA and least use in AP. The one striking exception was use of
MRAs, as described above.
Clinical outcomes
Despite the considerable heterogeneity in baseline characteristics
and treatment, the crude rate of all-cause mortality varied modestly
and was only clearly higher in one region—LA—compared with the
others. However, after adjustment the risk of all-cause and cardio-
vascular death was found to be higher in LA and in AP, compared
with NA. Both of the former regions also had the highest average
NT-proBNP levels and lower LVEF (mean 28%) compared with
the others (except NA which had the lowest LVEF–mean 27%).
However, the higher risk of death persisted (or even increased) after
adjusting for these and additional differences in known prognostic
variables suggesting other biological factors, social, and environmen-
tal influences or aspects of health care provision in these regions
contribute to the observed differences in survival. There may also
be geographical differences in the treatment of comorbidities such
as coronary artery disease, CKD, and AF which might also affect
outcome.
Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome
Study With Tolvaptan (EVEREST), the only other large trial report-
ing long-term outcomes according to region (in patients with acute
HF), observed similar crude mortality rates in NA, LA, and WE (no
patients from AP were included).7 The adjusted risk of death was
highest in LA. The Aliskiren Trial on Acute Heart Failure Outcomes
(ASTRONAUT), another acute HF trial, is the only study to have
reported outcomes in AP as well as the Americas and Europe.11
In that study, all-cause mortality at 12 months was highest in AP
(and high in LA). Interestingly, however, these other two studies re-
ported quite different findings about EE with the lowest risk of death
in that region in EVEREST but the second highest (after AP) in
ASTRONAUT. There has been recent controversy about a low
event rate in CEER17 and it is interesting that both PARADIGM-HF
and ASTRONAUT did not observe low event rates in this region.
Notably, unlike EVEREST, both PARADIGM-HF and ASTRONAUT
required elevated natriuretic peptides for inclusion, perhaps helping
ensure correct diagnosis and selection of patients at risk of events.
Greater variation in HF hospitalization rates, compared with
mortality, might have been predicted, given the likely differences
in decision making about admission, community programmes to
prevent hospitalization, thresholds for admission and even provision
and availability of hospital beds between regions. However, again,
only one region was clearly different from the others and that was
NA, which had almost twice the crude rate of HF hospitalization
compared with LA, although the differences between regions
were greatly attenuated by adjustment, with only WE having a
significantly lower risk. There was also no convincing evidence of
‘competing risk’ influencing our findings, i.e. regions with higher
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mortality did not consistently have lower admission rates. In
ASTRONAUT, NA patients also had a much higher unadjusted
HF hospitalization rate than elsewhere, although in EVEREST the
crude re-admission rates did not vary greatly between regions.7,11
Health-related quality of life
We are not aware of prior reports of geographic variation in
patient-reported outcomes. A clinically important deterioration in
KCCQ-CSS after 8 months was significantly less likely in LA and
AP (in unadjusted analyses) than elsewhere and it is notable that
these two regions had the highest baseline KCCQ-CSS (i.e. the
best HRQL). This finding illustrates the clear discrepancy between
patient-reported outcomes and clinical events, given that these
two regions had the highest all-cause and cardiovascular mortality
rates.
Treatment effect
Despite the differences highlighted, we did not identify any modifi-
cation of the effect of sacubitril/valsartan by geographical region—
the benefit over enalapril was consistent for all outcomes across all
regions, contrasting with controversy about consistency of benefit
of b-blockers in HF-REF and spironolactone in HF with preserved
ejection fraction (HF-PEF).15–17
Implications
Globalization of clinical trials is a reality that has highlighted regional
disparities of many types.2,9,13 Some are demographic and biologic-
ally determined and unavoidable whereas others reflect variation in
clinical practice and economic influences. Despite this, we found
that the key outcomes constituting trial endpoints varied less than
has been suggested previously. This may reflect more standardized
inclusion and exclusion criteria in HF-REF trials compared with trials
in HF-PEF and acute HF, and, in PARADIGM-HF in particular, the
use of a natriuretic peptide inclusion criterion. The latter may be
an even more important consideration in trials in patients with
(HF-PEF).12 Although we found no variation in treatment effect by
region, inevitably questions will also remain about the applicability of
the findings of trials enrolling a large proportion of patients from
regions where certain evidence-based therapies are substantially
underused (e.g. MRAs in NA and ICDs in the rest of the world).
Limitations
Our study has a number of limitations. Although PARADIGM-HF is
the largest HF trial to date, it is a single study. The analyses con-
ducted were retrospective and PARADIGM-HF was not designed
to evaluate geographical differences in HF. Because our analyses
involved comparisons of many different variables across several re-
gions, statistically significant differences may have arisen through the
play of chance. Although we performed multivariable adjustments,
we may not have captured the effect of all predictors influencing
the outcomes studied. While we examined recognized geographical
regions, differences may also exist between countries within these
regions and these may be more marked in some regions than others,
e.g. AP compared with NA. The number of patients recruited in NA
was limited (n ¼ 622), although analyses showed similar benefit for
these patients compared with other regions. The low number of
black patients (n ¼ 6) in WE probably reflects selection bias in trial
enrolment. As with any trial, the generalizability of the findings to
‘real-world’ patients may be limited.
Conclusion
There were many regional differences in PARADIGM-HF, including
in age, symptoms, comorbidity, background therapy, and
event-rates, although these did not modify the benefit of sacubi-
tril/valsartan.
Supplementary material
Supplementary material is available at European Heart Journal online.
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